内科理论与实践 ›› 2022, Vol. 17 ›› Issue (05): 369-372.doi: 10.16138/j.1673-6087.2022.05.004
陆林, 代杨, 王晓群, 吴立群, 张瑞岩, 沈卫峰
收稿日期:
2022-09-05
出版日期:
2022-09-30
发布日期:
2022-11-04
LU Lin, DAI Yang, WANG Xiaoqun, et al
Received:
2022-09-05
Online:
2022-09-30
Published:
2022-11-04
中图分类号:
陆林, 代杨, 王晓群, 吴立群, 张瑞岩, 沈卫峰. 心血管转化研究的若干进展[J]. 内科理论与实践, 2022, 17(05): 369-372.
LU Lin, DAI Yang, WANG Xiaoqun, et al. Several advances of translational research in cardiovascular diseases[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 369-372.
[1] |
Lam MP, Ping P, Murphy E. Proteomics research in cardiovascular medicine and biomarker discovery[J]. J Am Coll Cardiol, 2016, 68(25): 2819-2830.
doi: S0735-1097(16)36779-1 pmid: 28007144 |
[2] |
Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure[J]. Heart Fail Rev, 2022, 27(2): 625-643.
doi: 10.1007/s10741-021-10105-w URL |
[3] |
Kullo IJ, Cooper LT. Early identification of cardiovascular risk using genomics and proteomics[J]. Nat Rev Cardiol, 2010, 7(6): 309-317.
doi: 10.1038/nrcardio.2010.53 pmid: 20440292 |
[4] | de Boer RA, De Keulenaer G, Bauersachs J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure[J]. Eur Heart J, 2019, 21(3): 272-285. |
[5] |
Atienza F, Martins RP, Jalife J. Translational research in atrial fibrillation[J]. Circ Arrhythm Electrophysiol, 2012, 5(6): 1207-1215.
doi: 10.1161/CIRCEP.111.970335 pmid: 23022707 |
[6] |
Nattel S, Heijman J, Zhou L, et al. Molecular basis of atrial fibrillation pathophysiology and therapy[J]. Circ Res, 2020, 127(1): 51-72.
doi: 10.1161/CIRCRESAHA.120.316363 URL |
[7] |
Alonso R, Mata P, Muñiz O, et al. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia[J]. Atherosclerosis, 2016, 254: 249-253.
doi: S0021-9150(16)31306-5 pmid: 27594539 |
[8] |
Laugsand LE, Åsvold BO, Vatten LJ, et al. Circulating PCSK9 and risk of myocardial infarction[J]. JACC Basic Transl Sci, 2016, 1(7): 568-575.
doi: 10.1016/j.jacbts.2016.06.007 pmid: 30167541 |
[9] |
Shapiro MD, Tavori H, Fazio S. PCSK9: from basic science discoveries to clinical trials[J]. Circ Res, 2018, 122(10): 1420-1438.
doi: 10.1161/CIRCRESAHA.118.311227 pmid: 29748367 |
[10] | Shapiro MD, Fazio S, Tavori H. Targeting PCSK9 for therapeutic gains[J]. Curr Atheroscler Rep, 2015, 17(4): 499. |
[11] | Fitzgerald K, Simon A, White S, et al. A subcutaneously administered investigational RNAi therapeutic (ALN-PCSsc), targeting PCSK9 for the treatment of hypercholesterolemia: initial phase Ⅰ study results[C/OL]. http://www.pcsk9forum.org/wp-content/uploads/aln_pcssc_phase_ I_ data.pdf. |
[12] |
Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden[J]. Eur Heart J, 2017, 38(32): 2499-2507.
doi: 10.1093/eurheartj/ehx260 pmid: 28637178 |
[13] |
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017, 376(18): 1713-1722.
doi: 10.1056/NEJMoa1615664 URL |
[14] |
Poller W, Dimmeler S, Heymans S, et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives[J]. Eur Heart J, 2018, 39(29): 2704-2716.
doi: 10.1093/eurheartj/ehx165 pmid: 28430919 |
[15] |
Ravi S, Mitchell T, Kramer P, et al. Mitochondria in monocytes and macrophages-implications for translational and basic research[J]. Int J Biochem Cell Biol, 2014, 53: 202-207.
doi: 10.1016/j.biocel.2014.05.019 pmid: 24863362 |
[16] | Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection[J]. Sci Signal, 2009, 2(100): ra81. |
[1] | 吴立群. 大道至简——肺静脉隔离新技术[J]. 内科理论与实践, 2022, 17(05): 357-359. |
[2] | 尹翔, 郑良荣. 经皮左心耳封堵预防心房颤动卒中的研究进展[J]. 内科理论与实践, 2022, 17(05): 392-395. |
[3] | 费镇涛, 陈牧, 李毅刚. 心房颤动导管消融后复发机制的研究进展[J]. 内科理论与实践, 2022, 17(05): 396-399. |
[4] | 张芝, 汤学超, 黄新苗, 秦永文. 脉冲电场消融在心房颤动中的应用[J]. 内科理论与实践, 2022, 17(05): 400-404. |
[5] | 徐敏, 张京岚. 非心脏手术后新发心房颤动患者的相关临床分析[J]. 内科理论与实践, 2022, 17(04): 334-336. |
[6] | 车在前, 赵冰, 王义辉, 朱会会, 王聿名, 祁星, 李梦娇, 陈影, 马丽, 陈尔真, 毛恩强. 胆脂复合型急性胰腺炎的临床特点分析[J]. 内科理论与实践, 2022, 17(01): 58-62. |
[7] | 白英, 刘心遥, 张溪林, 高兆芳, 史旭波, 邓可武. 规范抗凝对心房颤动住院患者预后的影响[J]. 内科理论与实践, 2021, 16(06): 409-412. |
[8] | 施仲伟. 回眸过去30年全球和中国的心血管疾病负担及其危险因素——1990年至2019年全球心血管疾病负担及其危险因素报告解读[J]. 诊断学理论与实践, 2021, 20(04): 349-355. |
[9] | 黄少华, 梁宗辉, 童欢, 管雪妮, 郭瑛, 张雁, 曹宾, 孙育民. 心脏磁共振评估强直性肌营养不良1型患者心肌纤维化的临床价值[J]. 诊断学理论与实践, 2021, 20(04): 362-367. |
[10] | 吴昊, 白英, 邓可武. 心外膜脂肪组织与心血管疾病和代谢性疾病[J]. 内科理论与实践, 2021, 16(03): 208-211. |
[11] | 王泽田, 吴春荣, 齐越, 徐丹, 孙科远, 唐建国. 外泌体蛋白质组学分析白念珠菌感染小鼠的标志物[J]. 外科理论与实践, 2021, 26(03): 262-268. |
[12] | 晏焕青, 谢琼虹, 尚达, 戴淑琪, 朱彤莹. 胎球蛋白A对腹膜透析患者冠状动脉钙化发生起始的影响因素分析[J]. 内科理论与实践, 2021, 16(01): 49-52. |
[13] | 刘彤, 王鑫. 心房颤动预后不良风险的评估策略[J]. 诊断学理论与实践, 2020, 19(06): 555-558. |
[14] | 吴歆, 耿旭强, 徐沪济. 多基因风险评分在复杂性状疾病中的应用进展[J]. 诊断学理论与实践, 2020, 19(05): 540-543. |
[15] | 陈鹏, 李涛. 胞外囊泡携带的非编码RNA在肝癌发生、发展中的作用[J]. 外科理论与实践, 2020, 25(05): 447-451. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||